Morgan Stanley analyst Judah Frommer assumed coverage of PTC Therapeutics (PTCT) with an Overweight rating and a price target of $70, up from $67. A renewed strategy and management team has yielded a string of regulatory submissions and an improved capital position with “multiple potential value inflecting catalysts” to come in 2025, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics initiated with a Sector Perform at Scotiabank
- PTC Therapeutics’ Earnings Call: Strong 2024 Amid Challenges
- Promising Growth and Financial Stability Make PTC Therapeutics a Strong Buy
- PTC Therapeutics Faces Regulatory and Revenue Challenges: Analyst Maintains Sell Rating
- PTC Therapeutics: Buy Rating Backed by Promising Clinical Catalysts and Solid Commercial Foundation